Machado-Joseph Disease: from first descriptions to new perspectives

Orphanet Journal of Rare Diseases

Manuela Lima²  Conceição Bettencourt¹ 

[1] Laboratorio de Biología Molecular, Instituto de Enfermedades Neurológicas de Guadalajara, Fundación Socio-Sanitaria de Castilla-La Mancha, Guadalajara, Spain;Institute for Molecular and Cellular Biology (IBMC), University of Porto, Porto, Portugal

关键词: SCA3;    Polyglutamine disorders;    CAG repeats;    ATXN3 gene;    Ataxin-3;   

Others  :  866842
DOI  :  10.1186/1750-1172-6-35

 received in 2010-09-07, accepted in 2011-06-02,  发布年份 2011

【 摘 要 】

Machado-Joseph Disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), represents the most common form of SCA worldwide. MJD is an autosomal dominant neurodegenerative disorder of late onset, involving predominantly the cerebellar, pyramidal, extrapyramidal, motor neuron and oculomotor systems; although sharing features with other SCAs, the identification of minor, but more specific signs, facilitates its differential diagnosis. MJD presents strong phenotypic heterogeneity, which has justified the classification of patients into three main clinical types. Main pathological lesions are observed in the spinocerebellar system, as well as in the cerebellar dentate nucleus. MJD's causative mutation consists in an expansion of an unstable CAG tract in exon 10 of the ATXN3 gene, located at 14q32.1. Haplotype-based studies have suggested that two main founder mutations may explain the present global distribution of the disease; the ancestral haplotype is of Asian origin, and has an estimated age of around 5,800 years, while the second mutational event has occurred about 1,400 years ago. The ATXN3 gene encodes for ataxin-3, which is ubiquitously expressed in neuronal and non-neuronal tissues, and, among other functions, is thought to participate in cellular protein quality control pathways. Mutated ATXN3 alleles consensually present about 61 to 87 CAG repeats, resulting in an expanded polyglutamine tract in ataxin-3. This altered protein gains a neurotoxic function, through yet unclear mechanisms. Clinical variability of MJD is only partially explained by the size of the CAG tract, which leaves a residual variance that should be explained by still unknown additional factors. Several genetic tests are available for MJD, and Genetic Counseling Programs have been created to better assist the affected families, namely on what concerns the possibility of pre-symptomatic testing. The main goal of this review was to bring together updated knowledge on MJD, covering several aspects from its initial descriptions and clinical presentation, through the discovery of the causative mutation, its origin and dispersion, as well as molecular genetics aspects considered essential for a better understanding of its neuropathology. Issues related with molecular testing and Genetic Counseling, as well as recent progresses and perspectives on genetic therapy, are also addressed.

【 授权许可】

   
2011 Bettencourt and Lima; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Soong BW, Paulson HL: Spinocerebellar ataxias: an update. Curr Opin Neurol 2007, 20(4):438-446.
• [2]Carlson KM, Andresen JM, Orr HT: Emerging pathogenic pathways in the spinocerebellar ataxias. Curr Opin Genet Dev 2009, 19(3):247-253.
• [3]Tsuji S, Onodera O, Goto J, Nishizawa M: Sporadic ataxias in Japan--a population-based epidemiological study. Cerebellum 2008, 7(2):189-197.
• [4]Coutinho P, Andrade C: Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 1978, 28(7):703-709.
• [5]Stevanin G, Le Guern E, Ravise N, Chneiweiss H, Durr A, Cancel G, Vignal A, Boch AL, Ruberg M, Penet C, et al.: A third locus for autosomal dominant cerebellar ataxia type I maps to chromosome 14q24.3-qter: evidence for the existence of a fourth locus. Am J Hum Genet 1994, 54(1):11-20.
• [6]Shao J, Diamond MI: Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 2007, 16(Spec No. 2):R115-123.
• [7]Nakano KK, Dawson DM, Spence A: Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology 1972, 22(1):49-55.
• [8]Woods BT, Schaumburg HH: Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci 1972, 17(2):149-166.
• [9]Rosenberg RN, Nyhan WL, Bay C, Shore P: Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology 1976, 26(8):703-714.
• [10]Romanul FC, Fowler HL, Radvany J, Feldman RG, Feingold M: Azorean disease of the nervous system. N Engl J Med 1977, 296(26):1505-1508.
• [11]van de Warrenburg BP, Sinke RJ, Verschuuren-Bemelmans CC, Scheffer H, Brunt ER, Ippel PF, Maat-Kievit JA, Dooijes D, Notermans NC, Lindhout D, et al.: Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 2002, 58(5):702-708.
• [12]Schols L, Bauer P, Schmidt T, Schulte T, Riess O: Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004, 3(5):291-304.
• [13]Teive HA, Munhoz RP, Raskin S, Werneck LC: Spinocerebellar ataxia type 6 in Brazil. Arq Neuropsiquiatr 2008, 66(3B):691-694.
• [14]Jardim LB, Silveira I, Pereira ML, Ferro A, Alonso I, do Ceu Moreira M, Mendonca P, Ferreirinha F, Sequeiros J, Giugliani R: A survey of spinocerebellar ataxia in South Brazil - 66 new cases with Machado-Joseph disease, SCA7, SCA8, or unidentified disease-causing mutations. J Neurol 2001, 248(10):870-876.
• [15]Vale J, Bugalho P, Silveira I, Sequeiros J, Guimaraes J, Coutinho P: Autosomal dominant cerebellar ataxia: frequency analysis and clinical characterization of 45 families from Portugal. Eur J Neurol 2010, 17(1):124-8.
• [16]Silveira I, Coutinho P, Maciel P, Gaspar C, Hayes S, Dias A, Guimaraes J, Loureiro L, Sequeiros J, Rouleau GA: Analysis of SCA1, DRPLA, MJD, SCA2, and SCA6 CAG repeats in 48 Portuguese ataxia families. Am J Med Genet 1998, 81(2):134-138.
• [17]Zhao Y, Tan EK, Law HY, Yoon CS, Wong MC, Ng I: Prevalence and ethnic differences of autosomal-dominant cerebellar ataxia in Singapore. Clin Genet 2002, 62(6):478-481.
• [18]Tang B, Liu C, Shen L, Dai H, Pan Q, Jing L, Ouyang S, Xia J: Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neurol 2000, 57(4):540-544.
• [19]Jiang H, Tang BS, Xu B, Zhao GH, Shen L, Tang JG, Li QH, Xia K: Frequency analysis of autosomal dominant spinocerebellar ataxias in mainland Chinese patients and clinical and molecular characterization of spinocerebellar ataxia type 6. Chin Med J (Engl) 2005, 118(10):837-843.
• [20]Schols L, Amoiridis G, Buttner T, Przuntek H, Epplen JT, Riess O: Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 1997, 42(6):924-932.
• [21]Maruyama H, Izumi Y, Morino H, Oda M, Toji H, Nakamura S, Kawakami H: Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients. Am J Med Genet 2002, 114(5):578-583.
• [22]Shibata-Hamaguchi A, Ishida C, Iwasa K, Yamada M: Prevalence of spinocerebellar degenerations in the Hokuriku district in Japan. Neuroepidemiology 2009, 32(3):176-183.
• [23]Kraft S, Furtado S, Ranawaya R, Parboosingh J, Bleoo S, McElligott K, Bridge P, Spacey S, Das S, Suchowersky O: Adult onset spinocerebellar ataxia in a Canadian movement disorders clinic. Can J Neurol Sci 2005, 32(4):450-458.
• [24]Moseley ML, Benzow KA, Schut LJ, Bird TD, Gomez CM, Barkhaus PE, Blindauer KA, Labuda M, Pandolfo M, Koob MD, et al.: Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 1998, 51(6):1666-1671.
• [25]Alonso E, Martinez-Ruano L, De Biase I, Mader C, Ochoa A, Yescas P, Gutierrez R, White M, Ruano L, Fragoso-Benitez M, et al.: Distinct distribution of autosomal dominant spinocerebellar ataxia in the Mexican population. Mov Disord 2007, 22(7):1050-1053.
• [26]Storey E, du Sart D, Shaw JH, Lorentzos P, Kelly L, McKinley Gardner RJ, Forrest SM, Biros I, Nicholson GA: Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. Am J Med Genet 2000, 95(4):351-357.
• [27]Saleem Q, Choudhry S, Mukerji M, Bashyam L, Padma MV, Chakravarthy A, Maheshwari MC, Jain S, Brahmachari SK: Molecular analysis of autosomal dominant hereditary ataxias in the Indian population: high frequency of SCA2 and evidence for a common founder mutation. Hum Genet 2000, 106(2):179-187.
• [28]Krishna N, Mohan S, Yashavantha BS, Rammurthy A, Kiran Kumar HB, Mittal U, Tyagi S, Mukerji M, Jain S, Pal PK, et al.: SCA 1, SCA 2 & SCA 3/MJD mutations in ataxia syndromes in southern India. Indian J Med Res 2007, 126(5):465-470.
• [29]Bryer A, Krause A, Bill P, Davids V, Bryant D, Butler J, Heckmann J, Ramesar R, Greenberg J: The hereditary adult-onset ataxias in South Africa. J Neurol Sci 2003, 216(1):47-54.
• [30]Brusco A, Gellera C, Cagnoli C, Saluto A, Castucci A, Michielotto C, Fetoni V, Mariotti C, Migone N, Di Donato S, et al.: Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch Neurol 2004, 61(5):727-733.
• [31]Coutinho P: Doença de Machado-Joseph: Tentativa de definição. PhD Dissertation, Instituto de Ciências Biomédicas Abel Salazar, Porto; 1992.
• [32]Maciel P, Costa MC, Ferro A, Rousseau M, Santos CS, Gaspar C, Barros J, Rouleau GA, Coutinho P, Sequeiros J: Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 2001, 58(11):1821-1827.
• [33]Bettencourt C, Santos C, Kay T, Vasconcelos J, Lima M: Analysis of segregation patterns in Machado-Joseph disease pedigrees. J Hum Genet 2008, 53(10):920-923.
• [34]Lima L, Coutinho P: Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. Neurology 1980, 30(3):319-322.
• [35]Carvalho DR, La Rocque-Ferreira A, Rizzo IM, Imamura EU, Speck-Martins CE: Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr Neurol 2008, 38(4):296-299.
• [36]Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB: Survival estimates for patients with Machado-Joseph disease (SCA3). Clin Genet 2007, 72(6):543-545.
• [37]Suite ND, Sequeiros J, McKhann GM: Machado-Joseph disease in a Sicilian-American family. J Neurogenet 1986, 3(3):177-182.
• [38]Sakai T, Kawakami H: Machado-Joseph disease: A proposal of spastic paraplegic subtype. Neurology 1996, 46(3):846-847.
• [39]Iwabuchi K, Tsuchiya K, Uchihara T, Yagishita S: Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. Rev Neurol (Paris) 1999, 155(4):255-270.
• [40]Rub U, Brunt ER, Deller T: New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 2008, 21(2):111-116.
• [41]Yamada M, Sato T, Tsuji S, Takahashi H: CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115(1):71-86.
• [42]Horimoto Y, Matsumoto M, Akatsu H, Kojima A, Yoshida M, Nokura K, Yuasa H, Katada E, Yamamoto T, Kosaka K, et al.: Longitudinal study on MRI intensity changes of Machado-Joseph disease: correlation between MRI findings and neuropathological changes. J Neurol 2011, in press.
• [43]Rub U, de Vos RA, Schultz C, Brunt ER, Paulson H, Braak H: Spinocerebellar ataxia type 3 (Machado-Joseph disease): severe destruction of the lateral reticular nucleus. Brain 2002, 125(Pt 9):2115-2124.
• [44]Rub U, Brunt ER, Gierga K, Schultz C, Paulson H, de Vos RA, Braak H: The nucleus raphe interpositus in spinocerebellar ataxia type 3 (Machado-Joseph disease). J Chem Neuroanat 2003, 25(2):115-127.
• [45]Yamada M, Tan CF, Inenaga C, Tsuji S, Takahashi H: Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases. Neuropathol Appl Neurobiol 2004, 30(6):665-675.
• [46]Spinocerebellar Ataxia Type 3 [http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=sca3] webcite
• [47]Eto K, Sumi SM, Bird TD, McEvoy-Bush T, Boehnke M, Schellenberg G: Family with dominantly inherited ataxia, amyotrophy, and peripheral sensory loss. Spinopontine atrophy or Machado-Joseph Azorean disease in another non-Portuguese family? Arch Neurol 1990, 47(9):968-974.
• [48]Sudarsky L, Coutinho P: Machado-Joseph disease. Clin Neurosci 1995, 3(1):17-22.
• [49]Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, Chneiweiss H, Benomar A, Lyon-Caen O, Julien J, et al.: Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996, 39(4):490-499.
• [50]Paulson HL, Das SS, Crino PB, Perez MK, Patel SC, Gotsdiner D, Fischbeck KH, Pittman RN: Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 1997, 41(4):453-462.
• [51]Robitaille Y, Lopes-Cendes I, Becher M, Rouleau G, Clark AW: The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol 1997, 7(3):901-926.
• [52]Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, Klockgether T, Volpel M, Epplen JT, Schols L, et al.: An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 1998, 8(4):669-679.
• [53]Gilman S: The spinocerebellar ataxias. Clin Neuropharmacol 2000, 23(6):296-303.
• [54]Yamada M, Hayashi S, Tsuji S, Takahashi H: Involvement of the cerebral cortex and autonomic ganglia in Machado-Joseph disease. Acta Neuropathol 2001, 101(2):140-144.
• [55]Koeppen AH: The pathogenesis of spinocerebellar ataxia. Cerebellum 2005, 4(1):62-73.
• [56]Wang YG, Du J, Wang JL, Chen J, Chen C, Luo YY, Xiao ZQ, Jiang H, Yan XX, Xia K, et al.: Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic. J Neurol Sci 2009, 285(1-2):121-4. 15
• [57]Imon Y, Katayama S, Kawakami H, Murata Y, Oka M, Nakamura S: A necropsied case of Machado-Joseph disease with a hyperintense signal of transverse pontine fibres on long TR sequences of magnetic resonance images. J Neurol Neurosurg Psychiatry 1998, 64(1):140-141.
• [58]Murata Y, Yamaguchi S, Kawakami H, Imon Y, Maruyama H, Sakai T, Kazuta T, Ohtake T, Nishimura M, Saida T, et al.: Characteristic magnetic resonance imaging findings in Machado-Joseph disease. Arch Neurol 1998, 55(1):33-37.
• [59]Yamada S, Nishimiya J, Nakajima T, Taketazu F: Linear high intensity area along the medial margin of the internal segment of the globus pallidus in Machado-Joseph disease patients. J Neurol Neurosurg Psychiatry 2005, 76(4):573-575.
• [60]Lee YC, Liu CS, Wu HM, Wang PS, Chang MH, Soong BW: The 'hot cross bun' sign in the patients with spinocerebellar ataxia. Eur J Neurol 2009, 16(4):513-516.
• [61]De Oliveira MS, D'Abreu A, Franca MC Jr, Lopes-Cendes I, Cendes F, Castellano G: MRI-Texture Analysis of Corpus Callosum, Thalamus, Putamen, and Caudate in Machado-Joseph Disease. J Neuroimaging 2010, in press.
• [62]Klockgether T, Skalej M, Wedekind D, Luft AR, Welte D, Schulz JB, Abele M, Burk K, Laccone F, Brice A, et al.: Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 1998, 121(Pt 9):1687-1693.
• [63]D'Abreu A, Franca M, Appenzeller S, Lopes-Cendes I, Cendes F: Axonal dysfunction in the deep white matter in Machado-Joseph disease. J Neuroimaging 2009, 19(1):9-12.
• [64]Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, Shimazaki H, Soutome M, Endo K, Ohta S, et al.: The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 1993, 4(3):300-304.
• [65]Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, et al.: CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994, 8(3):221-228.
• [66]Ichikawa Y, Goto J, Hattori M, Toyoda A, Ishii K, Jeong SY, Hashida H, Masuda N, Ogata K, Kasai F, et al.: The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet 2001, 46(7):413-422.
• [67]Bettencourt C, Santos C, Montiel R, Costa MC, Cruz-Morales P, Santos LR, Simões N, Kay T, Vasconcelos J, Maciel P, et al.: Increased transcript diversity: novel splicing variants of Machado-Joseph Disease gene (ATXN3). Neurogenetics 2010, 11(2):193-202.
• [68]Takiyama Y, Sakoe K, Nakano I, Nishizawa M: Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology 1997, 49(2):604-606.
• [69]Quan F, Egan R, DB J, Popovich B: An unusually small 55 repeat MJD1 CAG allele in a patient with Machado-Joseph disease [abstract]. Am J Hum Genet 1997, 61:A318.
• [70]van Schaik IN, Jobsis GJ, Vermeulen M, Keizers H, Bolhuis PA, de Visser M: Machado-Joseph disease presenting as severe asymmetric proximal neuropathy. J Neurol Neurosurg Psychiatry 1997, 63(4):534-536.
• [71]van Alfen N, Sinke RJ, Zwarts MJ, Gabreels-Festen A, Praamstra P, Kremer BP, Horstink MW: Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001, 49(6):805-807.
• [72]Gu W, Ma H, Wang K, Jin M, Zhou Y, Liu X, Wang G, Shen Y: The shortest expanded allele of the MJD1 gene in a Chinese MJD kindred with autonomic dysfunction. Eur Neurol 2004, 52(2):107-111.
• [73]Padiath QS, Srivastava AK, Roy S, Jain S, Brahmachari SK: Identification of a novel 45 repeat unstable allele associated with a disease phenotype at the MJD1/SCA3 locus. Am J Med Genet B Neuropsychiatr Genet 2005, 133B(1):124-126.
• [74]Walker FO: Huntington's disease. Lancet 2007, 369(9557):218-228.
• [75]Goto J, Watanabe M, Ichikawa Y, Yee SB, Ihara N, Endo K, Igarashi S, Takiyama Y, Gaspar C, Maciel P, et al.: Machado-Joseph disease gene products carrying different carboxyl termini. Neurosci Res 1997, 28(4):373-377.
• [76]Alternative Splicing Prediction DataBase [http://www.caspur.it/ASPicDB] webcite
• [77]Gales L, Cortes L, Almeida C, Melo CV, do Carmo Costa M, Maciel P, Clarke DT, Damas AM, Macedo-Ribeiro S: Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. J Mol Biol 2005, 353(3):642-654.
• [78]Tzvetkov N, Breuer P: Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes. Biol Chem 2007, 388(9):973-978.
• [79]Albrecht M, Golatta M, Wullner U, Lengauer T: Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 2004, 271(15):3155-3170.
• [80]Riess O, Rub U, Pastore A, Bauer P, Schols L: SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008, 7(2):125-137.
• [81]Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R: A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123(5):773-786.
• [82]Todi SV, Winborn BJ, Scaglione KM, Blount JR, Travis SM, Paulson HL: Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J 2009, 28(4):372-382.
• [83]Ferro A, Carvalho AL, Teixeira-Castro A, Almeida C, Tome RJ, Cortes L, Rodrigues AJ, Logarinho E, Sequeiros J, Macedo-Ribeiro S, et al.: NEDD8: a new ataxin-3 interactor. Biochim Biophys Acta 2007, 1773(11):1619-1627.
• [84]Li F, Macfarlan T, Pittman RN, Chakravarti D: Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 2002, 277(47):45004-45012.
• [85]Burnett BG, Pittman RN: The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci USA 2005, 102(12):4330-4335.
• [86]Rodrigues AJ, do Carmo Costa M, Silva TL, Ferreira D, Bajanca F, Logarinho E, Maciel P: Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death. Biochim Biophys Acta 1803(10):1154-1163.
• [87]do Carmo Costa M, Bajanca F, Rodrigues AJ, Tome RJ, Corthals G, Macedo-Ribeiro S, Paulson HL, Logarinho E, Maciel P: Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels. PLoS One 5(7):e11728.
• [88]Mauri PL, Riva M, Ambu D, De Palma A, Secundo F, Benazzi L, Valtorta M, Tortora P, Fusi P: Ataxin-3 is subject to autolytic cleavage. FEBS J 2006, 273(18):4277-4286.
• [89]Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN: Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19(2):333-344.
• [90]Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB: Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002, 51(3):302-310.
• [91]Evert BO, Schelhaas J, Fleischer H, de Vos RA, Brunt ER, Stenzel W, Klockgether T, Wullner U: Neuronal intranuclear inclusions, dysregulation of cytokine expression and cell death in spinocerebellar ataxia type 3. Clin Neuropathol 2006, 25(6):272-281.
• [92]Rub U, de Vos RA, Brunt ER, Sebesteny T, Schols L, Auburger G, Bohl J, Ghebremedhin E, Gierga K, Seidel K, et al.: Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol 2006, 16(3):218-227.
• [93]Gaspar C, Lopes-Cendes I, Hayes S, Goto J, Arvidsson K, Dias A, Silveira I, Maciel P, Coutinho P, Lima M, et al.: Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am J Hum Genet 2001, 68(2):523-528.
• [94]Martins S, Calafell F, Gaspar C, Wong VC, Silveira I, Nicholson GA, Brunt ER, Tranebjaerg L, Stevanin G, Hsieh M, et al.: Asian origin for the worldwide-spread mutational event in Machado-Joseph disease. Arch Neurol 2007, 64(10):1502-1508.
• [95]Lima M: Doença de Machado-Joseph nos Açores: Estudo epidemiológico, biodemográfico e genético. Ponta Delgada: University of the Azores; 1996.
• [96]Lima M, Mayer FM, Coutinho P, Abade A: Origins of a mutation: population genetics of Machado-Joseph disease in the Azores (Portugal). Hum Biol 1998, 70(6):1011-1023.
• [97]Bettencourt C, Silva-Fernandes A, Montiel R, Santos C, Maciel P, Lima M: Triplet Repeats: Features, Dynamics and Evolutionary Mechanisms. In Recent Advances in Molecular Biology and Evolution: Applications to Biological Anthropology. Edited by Santos C, Lima M. Kerala: Research Signpost; 2007:83-114.
• [98]Lima M, Costa MC, Montiel R, Ferro A, Santos C, Silva C, Bettencourt C, Sousa A, Sequeiros J, Coutinho P, et al.: Population genetics of wild-type CAG repeats in the Machado-Joseph disease gene in Portugal. Hum Hered 2005, 60(3):156-163.
• [99]Martins S, Calafell F, Wong VC, Sequeiros J, Amorim A: A multistep mutation mechanism drives the evolution of the CAG repeat at MJD/SCA3 locus. Eur J Hum Genet 2006, 14(8):932-940.
• [100]Sequeiros J: Análise genética da variação fenotípica na doença de Machado-Joseph. PhD Dissertation. Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto; 1989.
• [101]Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, Dawson DM, Sudarsky L, Guimaraes J, Loureiro JE, et al.: Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995, 57(1):54-61.
• [102]Maruyama H, Nakamura S, Matsuyama Z, Sakai T, Doyu M, Sobue G, Seto M, Tsujihata M, Oh-i T, Nishio T, et al.: Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. Hum Mol Genet 1995, 4(5):807-812.
• [103]Bettencourt C, Santos C, Montiel R, Kay T, Vasconcelos J, Maciel P, Lima M: The (CAG)(n) tract of Machado-Joseph Disease gene (ATXN3): a comparison between DNA and mRNA in patients and controls. Eur J Hum Genet 2009.
• [104]Takiyama Y, Igarashi S, Rogaeva EA, Endo K, Rogaev EI, Tanaka H, Sherrington R, Sanpei K, Liang Y, Saito M, et al.: Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet 1995, 4(7):1137-1146.
• [105]Lerer I, Merims D, Abeliovich D, Zlotogora J, Gadoth N: Machado-Joseph disease: correlation between the clinical features, the CAG repeat length and homozygosity for the mutation. Eur J Hum Genet 1996, 4(1):3-7.
• [106]Sobue G, Doyu M, Nakao N, Shimada N, Mitsuma T, Maruyama H, Kawakami S, Nakamura S: Homozygosity for Machado-Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 1996, 60(3):354-356.
• [107]Tsuji S: Molecular genetics of triplet repeats: unstable expansion of triplet repeats as a new mechanism for neurodegenerative diseases. Intern Med 1997, 36(1):3-8.
• [108]Bettencourt C, Fialho RN, Santos C, Montiel R, Bruges-Armas J, Maciel P, Lima M: Segregation distortion of wild-type alleles at the Machado-Joseph disease locus: a study in normal families from the Azores islands (Portugal). J Hum Genet 2008, 53(4):333-339.
• [109]Igarashi S, Takiyama Y, Cancel G, Rogaeva EA, Sasaki H, Wakisaka A, Zhou YX, Takano H, Endo K, Sanpei K, et al.: Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. Hum Mol Genet 1996, 5(7):923-932.
• [110]DeStefano AL, Cupples LA, Maciel P, Gaspar C, Radvany J, Dawson DM, Sudarsky L, Corwin L, Coutinho P, MacLeod P, et al.: A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. Am J Hum Genet 1996, 59(1):119-127.
• [111]van de Warrenburg BP, Hendriks H, Durr A, van Zuijlen MC, Stevanin G, Camuzat A, Sinke RJ, Brice A, Kremer BP: Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch-French cohort. Ann Neurol 2005, 57(4):505-512.
• [112]Jardim L, Silveira I, Pereira ML, do Ceu Moreira M, Mendonca P, Sequeiros J, Giugliani R: Searching for modulating effects of SCA2, SCA6 and DRPLA CAG tracts on the Machado-Joseph disease (SCA3) phenotype. Acta Neurol Scand 2003, 107(3):211-214.
• [113]Lopes-Cendes I, Silveira I, Maciel P, Gaspar C, Radvany J, Chitayat D, Babul R, Stewart J, Dolliver M, Robitaille Y, et al.: Limits of clinical assessment in the accurate diagnosis of Machado-Joseph disease. Arch Neurol 1996, 53(11):1168-1174.
• [114]Sequeiros J, Maciel P, Taborda F, Ledo S, Rocha JC, Lopes A, Reto F, Fortuna AM, Rousseau M, Fleming M, et al.: Prenatal diagnosis of Machado-Joseph disease by direct mutation analysis. Prenat Diagn 1998, 18(6):611-617.
• [115]Drusedau M, Dreesen JC, De Die-Smulders C, Hardy K, Bras M, Dumoulin JC, Evers JL, Smeets HJ, Geraedts JP, Herbergs J: Preimplantation genetic diagnosis of spinocerebellar ataxia 3 by (CAG)(n) repeat detection. Mol Hum Reprod 2004, 10(1):71-75.
• [116]Gonzalez C, Lima M, Kay T, Silva C, Santos C, Santos J: Short-term psychological impact of predictive testing for Machado-Joseph disease: depression and anxiety levels in individuals at risk from the Azores (Portugal). Community Genet 2004, 7(4):196-201.
• [117]Paul C, Martin I, do Rosario Silva M, Silva M, Coutinho P, Sequeiros J: Living with Machado-Joseph disease in a small rural community of the Tagus valley. Community Genet 1999, 2(4):190-195.
• [118]Sequeiros J: General Protocol of the National Program of Predictive Testing and Genetic Counselling in Machado-Joseph disease. In Predictive Testing in Machado-Joseph Disease (in Portuguese). Edited by Sequeiros J. Porto: UnIGENe-IBMC; 1996.
• [119]Lima M, Kay T, Vasconcelos J, Mota-Vieira L, Gonzalez C, Peixoto A, Abade A, MacLeod P, Graca R, Santos J: Disease knowledge and attitudes toward predictive testing and prenatal diagnosis in families with Machado-Joseph disease from the Azores Islands (Portugal). Community Genet 2001, 4(1):36-42.
• [120]Leite A, Paúl C, Sequeiros J: O bem-estar psicológico em individuos de risco para doenças neurológicas hereditárias de aparecimento tardio e controlos [article in Portuguese]. Psicologia, Saúde & Doença 2002, 3(4):113-118.
• [121]Rolim L, Leite A, Ledo S, Paneque M, Sequeiros J, Fleming M: Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I. Clin Genet 2006, 69(4):297-305.
• [122]Abe K, Itoyama Y: Psychological consequences of genetic testing for spinocerebellar ataxia in the Japanese. European Journal of Neurology 1997, 4:593-600.
• [123]Smith CO, Lipe HP, Bird TD: Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol 2004, 61(6):875-880.
• [124]Cancel G, Gourfinkel-An I, Stevanin G, Didierjean O, Abbas N, Hirsch E, Agid Y, Brice A: Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease. Hum Mutat 1998, 11(1):23-27.
• [125]Ogawa M: Pharmacological treatments of cerebellar ataxia. Cerebellum 2004, 3(2):107-111.
• [126]Correia M, Coutinho P, Silva MC, Guimaraes J, Amado J, Matos E: Evaluation of the effect of sulphametoxazole and trimethoprim in patients with Machado-Joseph disease. Rev Neurol 1995, 23(121):632-634.
• [127]Tuite PJ, Rogaeva EA, St George-Hyslop PH, Lang AE: Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995, 38(4):684-687.
• [128]Buhmann C, Bussopulos A, Oechsner M: Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord 2003, 18(2):219-221.
• [129]Wilder-Smith E, Tan EK, Law HY, Zhao Y, Ng I, Wong MC: Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci 2003, 213(1-2):25-28.
• [130]Nandagopal R, Moorthy SG: Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Postgrad Med J 2004, 80(944):363-365.
• [131]Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T: Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003, 126(Pt 4):965-973.
• [132]Mello KA, Abbott BP: Effect of sulfamethoxazole and trimethoprim on neurologic dysfunction in a patient with Joseph's disease. Arch Neurol 1988, 45(2):210-213.
• [133]Azulay JP, Blin O, Mestre D, Sangla I, Serratrice G: Contrast sensitivity improvement with sulfamethoxazole and trimethoprim in a patient with Machado-Joseph disease without spasticity. J Neurol Sci 1994, 123(1-2):95-99.
• [134]Sakai T, Matsuishi T, Yamada S, Komori H, Iwashita H: Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin. J Neural Transm Gen Sect 1995, 102(2):159-172.
• [135]Schulte T, Mattern R, Berger K, Szymanski S, Klotz P, Kraus PH, Przuntek H, Schols L: Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001, 58(9):1451-1457.
• [136]Monte TL, Rieder CR, Tort AB, Rockenback I, Pereira ML, Silveira I, Ferro A, Sequeiros J, Jardim LB: Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003, 107(3):207-210.
• [137]Shirasaki H, Ishida C, Nakajima T, Kamei H, Koide T, Fukuhara N: [A quantitative evaluation of spinocerebellar degeneration by an acoustic analysis--the effect of taltirelin hydrate on patients with Machado-Joseph disease]. Rinsho Shinkeigaku 2003, 43(4):143-148.
• [138]Takei A, Fukazawa T, Hamada T, Sohma H, Yabe I, Sasaki H, Tashiro K: Effects of tandospirone on "5-HT1A receptor-associated symptoms" in patients with Machado-Josephe disease: an open-label study. Clin Neuropharmacol 2004, 27(1):9-13.
• [139]Liu CS, Hsu HM, Cheng WL, Hsieh M: Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy. Acta Neurol Scand 2005, 111(6):385-390.
• [140]Underwood BR, Rubinsztein DC: Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. Cerebellum 2008, 7(2):215-221.
• [141]D'Abreu A, Franca MC, Paulson HL, Lopes-Cendes I: Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat Disord 2010, 16(1):2-7.
• [142]Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, Wuellner U: Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 2007, 362(3):734-739.
• [143]Rodrigues AJ, Coppola G, Santos C, Costa Mdo C, Ailion M, Sequeiros J, Geschwind DH, Maciel P: Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J 2007, 21(4):1126-1136.
• [144]Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, Paulson HL: Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003, 100(12):7195-7200.
• [145]Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, Deglon N: Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008, 3(10):e3341.
• [146]Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR: Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009, 27(5):478-484.